Gerimal en es it fr

Gerimal Brand names, Gerimal Analogs

Gerimal Brand Names Mixture

  • No information avaliable

Gerimal Chemical_Formula


Gerimal RX_link

No information avaliable

Gerimal fda sheet

Gerimal msds (material safety sheet)

Gerimal Synthesis Reference

No information avaliable

Gerimal Molecular Weight

591.741 g/mol

Gerimal Melting Point

No information avaliable

Gerimal H2O Solubility

No information avaliable

Gerimal State


Gerimal LogP


Gerimal Dosage Forms

Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet

Gerimal Indication

For use as an adjunct therapy for patients with dementia

Gerimal Pharmacology

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Gerimal Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Gerimal side effects and Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Gerimal Patient Information

No information avaliable

Gerimal Organisms Affected

Humans and other mammals